Mallinckrodt (MNKKQ)

OTC Markets
0.18
-0.01(-5.13%)
  • Volume:
    108,284
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    0.17 - 0.20

MNKKQ Overview

Prev. Close
0.19
Day's Range
0.17-0.2
Revenue
2.3B
Open
0.17
52 wk Range
0.11-0.8
EPS
-7.95
Volume
108,284
Market Cap
15.25M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
420,946
P/E Ratio
-
Beta
3.21
1-Year Change
-76%
Shares Outstanding
84,723,768
Next Earnings Date
Feb 22, 2022
What is your sentiment on Mallinckrodt?
or
Market is currently closed. Voting is open during market hours.

Mallinckrodt Company Profile

Employees
3086

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an acetaminophen injection; Therakos photopheresis, an immunotherapy treatment platform; and Amitiza for constipation. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; and SLN500, a ribonucleic acid technology therapy. In addition, it offers specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc for the development and commercialization of ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong BuyBuyStrong Sell
Technical IndicatorsSellSellStrong BuyStrong BuyStrong Sell
SummarySellSellStrong BuyStrong BuyStrong Sell
  • Can we get Trudaux fuq out?
    0
    • What about you, johns, why so afraid to buy more? Coz you are all cuckolds and school boys?
      0
      • I gave you a like)))
        0
      • im scared 😨
        0
    • Good morning! target new 15.70$
      1
      • why mnkkq charge 50 $ tomorrow ?
        0
        • why mnkkq charge 50 $ tomorrow ?
          0
          • Check NMTR, it has a lead medication called larazotide currently at phase 111 clinical trial for celiac disease with the potential of using it to reduce covid-induced respiratory symptoms! Buy and enjoy later analyst consensus price target at $6 but currently trading in pre market at $1.9
            2
            • What happened here? Any news?
              0
              • chapter 11
                3
                • https://finance.yahoo.com/news/buxton-helmsley-group-announces-sufficient-200200706.html
                  0
                  • is this news good or Bad for this stock?
                    0
                  • it gives a hope
                    0
                • Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease
                  0
                  • This is going to explode shortly from now
                    0
                    • what does it mean??? could u explain???
                      0
                    • it mean this.
                      0
                  • Why is this company is trading so low?! Does it have future?
                    0
                    • buy!!!
                      0
                      • AVGR +46%
                        0
                        • Heading straight to above 5usd per share before end of January 2021!
                          0
                          • I hope that you bought at >$.4 if you are so confident
                            0
                        • It's a bankrupt company: https://seekingalpha.com/news/3621280-mallinckrodt-files-for-chapter-11-for-opioid-settlement-and-debt-reduction The shares will be cancelled at the end of the bankruptcy procedure, do a little research before buying a share.
                          1
                          • Never. That's old news since 2months ago.This is going to beyond 5usd per share before the end of January 2021!
                            0
                          • 0
                        • This wont disappear. Invest $500 its going to make you $12k within 12 months.
                          0
                          • VelerofodiSs Valesi also had a lot in NIO when it was at $2
                            0
                          • Teach me I am New
                            0
                          • 10% down ... I can't believe it..how you believe to go?
                            0
                        • Hello, Is it tades somewhere on OTC? What is the ticker please? The company's site is no more operating?
                          0
                          • MNKKQ
                            0
                        • a go ? or no?
                          1
                          • legit
                            0
                            • lawyers killed this company and its investors
                              0
                              • Bankruptcy... Lesson learned when you play with fire... You get burnt, with no exceptions... "equity holders and non-guaranteed unsecured noteholders are expected to receive no recovery." Read more at: https://thefly.com/n.php?id=3173085
                                2
                                • is it stopped?
                                  0
                                  • I'm glad I sold 3 months ago, I saved a bunch of money.
                                    2
                                    • omg u r so clever that u need to come to this forum and post that.. here, the peanut for you
                                      1
                                    • ana kw Thanks *****
                                      0
                                    • I don't know why your name got with the character *, I guess upper case?
                                      0
                                  • bounce is quite possible
                                    2
                                    • No
                                      1
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.